Row Continues Over Soaring Mexican Prices

20 August 1995

Constantly soaring prices of medicines in Mexico since the December 20, 1994, peso devaluation have been the subject of continuous wrangling, with no end in sight.

There are differences of opinion as to the extent of drug price increases, reports the Marketletter's local correspondent, from a low of 40% to more accurate level of 100% and as much as 200%, with pharmacists, distributors and the government arguing about the upward trend, and the public complaining bitterly about the jump in prices, often coming from one week to the next.

No one at the Ministry of Commerce, the official price regulating body, wanted to comment on the situation, beyond noting that prices are rising for everything due to the devaluation.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight